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Introduction 
Synthetic data is used in a variety of industries in order to develop software and 
perform testing. Accurate synthetic data allows for all of the functionality of real data, but 
without privacy concerns. Synthetic health records can be used for research and 
development in the healthcare industry, without the risk of re-identification of real 
personal health records. Synthea is a synthetic patient generator that creates synthetic 
patient health records which can be used for the creation of new and improved 
electronic health record systems.  
This Major Qualifying Project (MQP) is concerned with validating and verifying 
that Synthea is creating realistic synthetic patient data at the patient level, disease 
module level, and population level. Through interviewing medical doctors, it was found 
that the individual synthetic health records were somewhat realistic representation of 
actual health records. Additionally, it was found that the pregnancy disease module in 
Synthea was missing information contained in published standards of care. The 
pregnancy module was updated to be more aligned with the standards of care. It was 
also found that Synthea is producing realistic and consistent disease prevalence levels.  
Background    
The United States is a global leader in science and technology, home of forty of 
the world’s top universities and accounting for about forty percent of the world’s total 
spending on research and development (“U.S. Still Leads the World in Science and 
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Technology; Nation Benefits From Foreign Scientists, Engineers”, 2008). Technology is 
advancing by the day, solving problems, bettering lives, and connecting people. With all 
of the advancements being made, it may be hard to believe that the United States 
healthcare industry still lags behind in technological advancements. In fact, many 
healthcare professionals do not advocate for the use of software in hospitals. Robert M. 
Wachter’s 2015 New York Time’s article Why Health Care Tech Is Still So Bad 
describes a hospital job posting in the Phoenix, Arizona area, boasting that they do not 
use an electronic medical record system (EMR) and using that as a “selling point”. 
Many sources including Athena Health, The New York Times, George Palma 
M.D., and Afia Health agree that while technology in the healthcare industry does 
promise to be transformative in the quality of care given to patients, it proves to be 
difficult to implement. EMRs can help to reduce human error in drug prescriptions, 
assist in real-time decision making, and make health records available to patients and 
outside hospitals in necessary situations including emergencies. However, with so many 
EMR solutions available, it is difficult to standardize the way patients are cared for, how 
payments and insurance are processed, how health records are organized, and how 
that data is shared. As of 2014, 76% of hospitals in the United States exchanged health 
information electronically (Swain et al., 2015), however the format of that data differs 
widely among EMRs (“The Challenges of Sharing Data Between Separate EHRs”, 
2017). Non-uniform data can be difficult to parse in real-time situations that require 
immediate attention. Health interoperability must contain a standardized way of 
communicating information and being able to use that information effectively and time-
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efficiently. Software developers and researchers need access to many health records in 
order to test and implement new health interoperability solutions. However, obtaining 
health records can be expensive and poses privacy risks, even if the records are de-
identified or anonymized. The use of synthetic data has been successful in the 
development of software in the financial industry. This synthetic data can model 
payments, withdrawals, and deposits, making a complete customer profile. A similar 
approach can be taken to model a synthetic patient health record in the healthcare 
industry. 
Synthetic health records can be used for research and development in the 
healthcare field, without the risk of re-identification of real personal health records. 
Synthea is a Synthetic Patient Population Simulator which aims to provide the realistic 
health data needed to improve healthcare technology solutions. It is open-source, free 
of cost, and has no restrictions. The goal of Synthea is to produce realistic, yet 
synthetic, patient data. With any synthetically generated data, the use of that data is 
only as reliable as the data itself. Synthea must be both verified and validated on the 
patient, module, and population levels in order to be accredited for specific use cases 
such as health data interoperability solutions.  
Health Data Interoperability  
Health data interoperability is the ability of two or more systems to exchange and 
make use of health information (“Obstacles to Interoperability within Closed Systems”, 
2017). Electronic Health Records (EHRs) contain information of a patient’s medical 
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history including demographics, medications, vital signs, immunizations, laboratory 
results and more (“Electronic Health Records”, 2012). EHRs theoretically allow for the 
sharing of health data between hospitals, doctors offices, surgery centers etc. and can 
have digital processes which allow for decision support in important situations as well as 
medical coding and billing. There are many benefits to EHRs including improved patient 
care, diagnostics, and patient participation. The Health Information Technology for 
Economic and Clinical Health (HITECH) Act of 2009 is meant to promote the meaningful 
use of health information technology in order to better healthcare experiences for all 
(“HITECH Act Enforcement Interim Final Rule”, 2017). 
While sharing EHRs aims to be beneficial for patients and healthcare providers 
alike, the data shared can be useless if one EHR cannot effectively communicate with 
another EHR. When EHRs were first coming into existence, the companies building 
them did not take into account the importance of communication across EHRs, rather 
they focused on building the system primarily for the purpose of medical billing. The 
data within EHRs must move towards a standardized format for communication 
between systems, and recorded in such a way that allows for complete and correct 
medical billing. For patients, it is also important that the data be thoroughly clinically 
detailed and be readily available to them through an online patient portal (Bresnick, 
2015).  
Data exchange across EHRs encompasses interactions with users, 
communication between systems, and how the data communicated is processed (“What 
Is EHR Interoperability and Why Is It Important?” 2013). Afia Health Inc. describes three 
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shortcomings of data exchange between EHR systems. The first shortcoming they 
describe is the difficulty of finding shared patients between systems, because EHRs 
identify patients in different ways and store them in different formats. The second 
shortcoming is the translation of data between EHRs and their coding standards; there 
are multiple medical billing and coding practices that exist and not all systems use the 
same set of codes. The final shortcoming Afia discusses is data storage; as more and 
more healthcare practices move to EHRs, it must be guaranteed that the system has 
the capacity to hold all required data and process necessary exchanges (“The 
Challenges of Sharing Data Between Separate EHRs”, 2017). George Palma, MD also 
discusses shortcomings including the difficulty of sharing health records between 
hospitals, and delays in documentation in his 2013 article “Electronic Health Records: 
The Good, the Bad and the Ugly”. All of these shortcoming point to the need for a more 
standardized way of recording, sharing, and storing EHRs. New solutions with improved 
data storage, communication abilities, patient portal access, and medical billing, must 
be tested with realistic and scalable health data.  
Synthetic Data Generation  
 Simulation models aim to be accurate representations of a real world system. 
Simulation models can be valuable in the healthcare field for the creation of new health 
data interoperability solutions and for research. These models must be realistic at the 
patient and population levels, in order to properly design solutions that fit the needs of 
both the patients and the health care practices using them. Invalid models result in 
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invalid conclusions, making the simulation model useless or possibly harmful in the 
worst-case scenario. Validation and verification of a model helps to ensure it is an 
accurate and valuable representation. Validation is the process of determining if the 
model is an accurate representation of the system; the associated question for 
validation is “Did we build the right model?” Verification is the process of determining if 
the simulation model works as it is intended to; the associated question for verification is 
“Did we build the model right?”. There are several techniques in practice for performing 
validation and verification (Systems Engineering Guide, 2014).  
 The MITRE Systems Engineering Guide (SEG) describes their verification, 
validation, and accreditation (VV&A) process as not only desirable for outcomes, but 
also essential. The SEG describes the verification phases as an iterative process which 
determines if each phase is complete, consistent, and correct, in order to move on to 
the next phase. Alternatively, the validation phases focus on comparing the system to 
the simulated model, and determining if the differences between them are acceptable or 
if they need to be adjusted. The final stage in their process is accreditation, which will 
state that the simulation model and the associated data are able to be used for a 
specific purpose. 
Verification Techniques 
Verification of a simulation model is concerned with the correct implementation 
and usage of the model. In Robert G. Sargent’s 2016 paper Verification and Validation 
of Simulation Models he explains that when a higher-level programming language is 
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used to create the model, the model should be designed, developed, and implemented 
using software engineering techniques (188-89). When using a higher-level 
programming language, verification is most often concerned with concluding that the 
simulator functions properly and that it was both programmed and implemented 
correctly. Testing simulation software is most often done through static and dynamic 
testing. Static testing uses techniques including structured analyses and examining the 
properties of the software. Dynamic testing takes advantage of techniques including 
traces, input-output investigations, internal checks, and the reprogramming of essential 
components (189). 
Antibugging is another approach to verifying simulations. Antibugging involves 
putting in additional checks such as counters, to ensure that the output of the program 
is what it was intended to be at each moment in time. Another approach to verifying 
simulations is a one-step analysis, in which the developer will explain the simulator 
step-by-step to either another person or to themselves to see if they have missed 
anything within the model or if their logic was flawed. Another verification technique is 
deterministic modeling. Deterministic modeling is when random variables are replaced 
with static variables in order to see if the model is behaving properly. Once it is 
determined that the model is correct, the values can then be changed back to random 
variables (Hillston, 2013).  
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Validation Techniques 
The MITRE SEG describes five commonly recommended simulation model 
validation techniques (462). The first technique is comparison to other models. This 
method involves comparing the model being created to other simulation models that 
have been previously validated for a similar purpose. Another technique described is 
face validity; this method involves consulting field experts regarding their opinion of the 
accuracy of the model’s behavior, logic, relationships etc. The next validation technique 
described is historical data validation. This method can be used if historical data exists 
for the simulation model being created. Some of the historical data can be used to 
create and build the model, while the remaining data can be used to test if the model 
behaves appropriately. Another technique explained is parameter variability - sensitivity 
analysis. In this technique, one would alter the inputs and internal parameters of the 
model to see if the output reflects that of the actual system output under those 
conditions. The last technique described is predictive validation which is when the 
model is used to forecast the actual system’s behavior, then the forecast and actual 
outcome are compared. 
Additional techniques, not described in the MITRE SEG but still worth 
considering for validation, include internal validity, traces, and Turing tests. Internal 
validity involves running multiple iterations of the model, and looking for variability 
among results as this may indicate that the model needs to be altered. Traces are when 
specific modules within the simulation are followed throughout the simulation; this helps 
to determine if the logic of the model is correct. Turing tests involve consulting a field 
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expert to see if they can determine differences between real world results and results 
from the simulation (Sargent, 2016). 
Synthea 
Synthea is a Synthetic Patient Population Simulator research project created by 
MITRE. MITRE is a not-for-profit company that operates Federally Funded Research 
and Development Centers (FFRDCs). Synthea was developed to address the need for 
health record datasets for use in the creation of innovative software development and 
other non-clinical use, where realistic data is necessary. Synthea can be used in 
academic settings for research and can be used by software developers to test the 
features of new health data interoperability solutions (Synthea Wiki, 2017).  
De-identified and anonymized health records can be used for the purposes of 
testing and software development in the healthcare field, however it is costly to acquire 
and poses risks of re-identification of the real people in the dataset. The data produced 
in Synthea is completely synthetic, open-source, and can be used in academics, 
research, and development. Unlike other synthetic EHR generators that exist, Synthea 
does not use de-identified data in the creation of their patients but rather it takes 
advantage of regional datasets, clinical practice guidelines (CPGs), and input from 
healthcare professionals. It supports and models the ten most common reasons why 
patients visit their primary care physicians, as well at the ten most common causes of 
death (Synthea Wiki, 2017).  
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A Generic Module Framework is used for creating the state machines of the 
diseases supported within Synthea. Each module is based on publically available data 
regarding disease incidence, prevalence, and progression as well as CPGs. Synthea 
uses an agent-based approach to generate the patients, one patient at a time. Each 
patient generated will go through each disease module within the system, simulating the 
progression and treatment of disease (Synthea Wiki, 2017).   
The modules are defined in JavaScript Object Notation (JSON) and describe the 
progression of states as well as the transitions between them. Each generated patient 
begins in an initial state when being processed through the disease modules, and will 
end in a terminal state meaning that no further steps will be taken within the module, or 
in a continuing loop of treatment. There are multiple possible states that can occur 
between the initial and terminal state, one of which being a simple state. A simple state 
will not add information or actions, it will simply progress to the next defined state in 
order to chain together a series of complicated or branching transitions. A guard state 
only allows the generated patient to progress beyond it if specific conditions are met, for 
example, a specified age or age range must be met. A delay state will not allow the 
patient to progress onto the following state until a certain amount of time has passed 
within the simulator. An encounter state will specify that a specific healthcare encounter 
has occurred and will add it to the patient record. There is also an encounter end state 
which specifies the end date of that encounter and will update the record (Synthea Wiki, 
2017).  
13 
There are similar states for conditions, allergies, medication orders, and care 
plans which have an onset and an end state. A procedure state indicates that a 
procedure has occurred during an encounter. The procedure also has an associated 
reason for the act. The vital sign state will indicate the physical state of the person at a 
certain time, for example during a doctor's office visit. The observation state is 
processed during an encounter and includes observations such as laboratory tests and 
findings. Similarly, the multi-observation state specifies the multiple observations that 
should be taken at that time. A diagnostic report state will group multiple observations 
into a single report. A symptom state will record and update the severity of a patient’s 
symptoms on a defined scale of 1-100, and the symptoms drive the care seeking 
behavior. The counter state will update the number of times something occurs in the 
patient’s life such as a disease occurrence. The last state of death, indicates that the 
patient has died or that they are within a terminal state that will end after the date of the 
generation (Synthea Wiki, 2017).  
Certain states have associated clinical codes for further information recording. 
Synthea supports Systematized Nomenclature of Medicine Clinical Terms (SNOMED-
CT) to describe clinical findings, diagnoses, symptoms, and more in the encounter, 
procedure, condition onset, and care plan start states. RxNorm codes are used within 
the medication order state to describe prescriptions and medications. Lastly, LOINC 
codes are used in the observation state for tests, measurements, and observations 
(Synthea Wiki, 2017).  
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There are a variety of transitions that can occur between states. A direct 
transition will simply transition to the next specified state. A distributed transition has a 
certain likelihood of the patient progressing through it; there are more than one 
distributed states, all of which will sum to 100% from a certain state. A conditional 
tradition will only occur is certain defined conditions are met. A complex transition 
combines direct, distributed, and conditional transitions (Synthea Wiki, 2017).   
The generated health records can be formatted in a number of ways depending 
on the needs of the user. Patients can be exported as Fast Healthcare Interoperability 
Resources (FHIR) which is a standard created by HL7 for the purpose of exchanging 
healthcare data electronically. Additionally Synthea can export the generated patients 
as Consolidated Clinical Document Architecture (C-CDA) which is also defined by HL7. 
Synthea can also export in HTML or simple text, for a more human-readable format. 
Lastly the patients can be exported in CSV format which can be useful for relational 
databases and Microsoft Excel. Synthea exports a total of nine CSV files including 
patients, encounters, allergies, medications, conditions, care plans, observations, 
procedures, and immunizations (Synthea Wiki, 2017).  
Over one million synthetic EHRs, generated by Synthea, contribute to another 
MITRE project, SyntheticMass. SyntheticMass provides realistic population and 
demographic data at the state, county, and town / city levels for Massachusetts at a 
1/7th scale. Additionally it has the added ability to filter and view male and female 
population levels, as well as diabetes, heart disease, and opioid addiction prevalence. 
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Alternatively, one can choose to view SyntheticMass with the census dataset instead of 
the Synthea-generated dataset (“About Synthetic Mass”, 2016).  
Care Maps / Clinical Pathways  
A clinical pathway or care map, as defined by BioMed Central (BMC) Medicine, is 
a tool used to guide evidence-based healthcare (Kinsman et al., 2010). Children’s 
Hospital of Philadelphia states that clinical pathways aim to standardize care for clinical 
problems, processes, and procedures. Clinical pathways serve as a way to perform best 
practices, based on existing evidence, and avoid unnecessary variations in treatments. 
As research furthers and better practices emerge, clinical pathways are updated to 
encourage best practices (“About the Clinical Pathways Program”, 2017). 
Synthea models the disease modules based on these clinical pathways, referring 
to them as “care maps”. In the future, MITRE hopes to have a web interface which 
would allow healthcare professionals to edit or modify the modules with no 
programming experience required.  
Synthea Review 
In 2017 Scott McLachlan published a thesis titled Realism in Synthetic Data 
Generation. Part of this thesis included a review of the Synthea SDG method. In his 
review he focused on the clinical pathways and data surrounding type-2 diabetes in 
Massachusetts. He found major disagreements between the prevalence of type-2 
diabetes among demographic populations in Synthea compared to the national CDC 
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statistics. Additionally he found the clinical pathways implemented in the disease 
module for type-2 diabetes within Synthea resulted in amputations for 100% of those 
diagnosed, which is drastically different than the reported 0.65% rate of diabetic-related 
amputations in Massachusetts.  
He also found that the diagnosis of kidney failure in Synthea among diabetics 
was not close to the actual average, with 87.06% of type-2 diabetic Synthea patients 
having kidney failure, in contrast to the 0.17% of diabetics actually affected by kidney 
failure. In addition to this inaccuracy, he also found that the Synthea patients would not 
undergo dialysis but continue to live for ten or more years; this is improbable as well 
because kidney failure requires ongoing dialysis or a kidney transplant in order to not 
result in a quick death, he explained.  
McLachlan lastly focused on the age of diagnosis of type-2 diabetics. Synthea 
diagnosed most patients around the age of 46, which is the mean age of diagnosis in 
the United States. However, Synthea failed to diagnose anyone over the age of 52, 
which is not in alignment with the actual average ages of diagnosis. Synthea also did 
not meet statistics in diagnosing many patients in the 11 years - 28 years age group. 
Lastly, Synthea diagnosed too many patients in the less than 10 years of age group, as 
type-2 diabetes diagnosis typically do not occur in young children.  
It is important to note that since that review was published, MITRE has actively 
worked to correct those abnormalities within Synthea. Synthea now produces much 
more realistic data regarding type-2 diabetes prevalence, treatment, and diagnosis. 
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McLachlan provided an in-depth analysis of one disease module that can be useful for 
future analysis of Synthea and its other existing modules.  
Synthea can be a great tool for developers looking to improve EHRs. Synthetic 
patient data allows developers to reap all the benefits of using real health data in their 
work, but without the risk of data breaches and at no cost. In order to be considered 
reliable for creating these new solutions, Synthea must be realistic on the patient, 
disease module, and population levels.  
Research Proposal 
This MQP will accomplish three different validations and verifications of Synthea. 
Firstly, the synthetic patient records will be verified to be realistic representations of 
health records. Second, the pregnancy disease module will be edited to contain 
necessary care and procedures, and then verified to be a realistic representation of a 
standard of care. Third, Synthea will be validated at the population level, specifically 
validating that the disease prevalence levels are realistic compared to published data 
regarding disease prevalence. This project is concerned with the validating the realism 
of Synthea for the purposes of software development of EHR solutions and other non-
clinical secondary use. It will also help the Synthea team to assess what changes they 
may need to make to the simulator to improve its suitability. 
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Synthetic Patient Health Record 
The hypothesis for the synthetic patient health records is that they are realistic 
representations of actual health records, and that the missing information is not crucial 
to the completeness of the health records. The records will be verified through 
interviews with six medical doctors, employed by MITRE. These interviews will be semi-
structured in order to allow for elaboration on answers and follow up questions. In these 
interviews the questions regarding how realistic they perceive the records to be, where 
information in the record appears to be missing, what type of information is missing, and 
how crucial it is to the health record that the information be there. The interview data will 
be recorded in a Qualtrics survey. This allows for quick access the data for analysis of 
the results. The results of the interviews, specifically where information is missing or 
incorrect, will help with correcting and providing suggestions for specific disease 
modules.  
Disease Module 
The hypothesis of the pregnancy disease module is that the lack of information in 
the module results in incorrect patient record detail. The disease modules in Synthea 
are based on standards of care and are detailed, but are also an abstraction of true care 
maps. This will require an initial analysis of the pregnancy disease module to identify 
where information is missing or incorrect. The module care plan will be compared 
against published care plans in order to find the necessary information to add.  
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After comparing the Synthea modules with actual care plans, the disease 
module, defined in JSON, will be edited to present realistic data in terms of prevalence 
and progression. This requires using parameter variability - sensitivity analysis as the 
validation technique, adjusting values within the module to see how they affect the 
outcomes and if those outcomes align with real world data. For verification, a one-step 
analysis will be conducted, in which the edited disease module is explained step by step 
to a field expert, to check that the logic of the module is clear and correct.  
Population Report 
The hypothesis for the population report is that the levels of disease prevalence 
across various demographics will be similar to real world data, but will vary slightly from 
actual statistics regarding prevalence, when those statistics are available, by a standard 
deviation of +/- 10%. A detailed report of disease prevalence across age, gender, and 
race will be created. This report will be created using the synthetic patients created in 
Synthea, and compared to United States and Massachusetts published statistics of 
prevalence. This report will be created by populating a database with the data, querying 
the results in Structured Query Language (SQL), and creating the report using Java.  
Internal validity will be used as the validation technique, populating many 
synthetic records and looking for noticeable variations between the outcomes will help 
to assess how accurate the synthetic data is and how often it is accurate. A one-step 
analysis for verification will be conducted in which it is explained step-by-step how the 
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report was created, how it was programmed, and how it can be edited to house 
additional information in the future to a MITRE colleague.  
Methodology  
 
Figure 1: Methodology 
This methodology is divided into three main objectives which accomplish the 
goals stated in the research proposal. The first objective is to interview medical doctors 
to verify the synthetic patient health records are realistic representations of actual health 
records. This method takes advantage of the WPI Qualtrics tool, used for interviews and 
surveys, in order to successfully organize and evaluate information. The second 
objective is to validate and verify the pregnancy module in Synthea is a realistic 
representation of published standards of care. This requires editing the module, and 
researching to find the necessary information to include within the module. The final 
objective is to create, and validate a population disease prevalence report has realistic 
prevalence levels compared to published data regarding disease prevalence. This uses 
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Java and SQL to query an H2 database containing information from individual profiles 
and organize the results into a report.  
Objective I: Interview Medical Doctors to Validate Synthetic 
Patient Health Records 
This objective began with collaboration with MITRE and WPI advisors to 
compose semi-structured interview questions, which covered the major questions, but 
also allowed for elaboration and follow up questions. The questions were formatted into 
a WPI Qualtrics survey in order to keep track of the data in real time and for efficient 
access. This also minimized the amount of decoding to be done following the 
interviews. Additionally, the interview questions were reviewed and approved by WPI’s 
Internal Review Board (IRB). Next, interviews were requested with six medical doctors, 
employed by MITRE. 
Selecting which patient profiles to use in the interviews proved to be a challenge. 
When the records are formatted as simple text, they are easy for humans to read but 
contain less detailed information compared to when the records are formatted in FHIR; 
however the FHIR format is more difficult for humans without a computer science 
background to understand. The FHIR profiles contain personal information such as 
maiden name, address, socioeconomic status, education level, and primary language 
spoken. They also contain additional information for procedures and encounters that the 
text files do not have including a start and end time. The FHIR files contain patient goals 
that are not defined in the text files as well, such as keeping a blood pressure below a 
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certain threshold. The FHIR profiles also contain additional observations including 
height, weight, BMI, blood pressure, and blood glucose levels.  
Although the FHIR records are more detailed, they are also much longer. For 
example, one of the patient profiles used during the interviews was 329 lines in the text 
format, but was 50,273 lines in the FHIR format. Ultimately, five patient records, 
generated by the ruby version of Synthea and formatted as text files, were selected for 
use during the interviews with the M.D.s. Records with patients of various ages, race, 
gender, and diseases were selected.  
The interviews were conducted over phone calls and the patient profiles were 
sent over to the M.D.s via email in a PDF format. At the beginning of each call, the 
format of the health record and what they could expect to see within the record was 
explained. The same set of questions were asked for each patient to ensure that similar 
data was collected for each record. The responses were recorded in the Qualtrics. The 
open-ended questions allowed for follow-up questions as well.  
Objective II: Validate and Verify Pregnancy Module 
This objective started with researching pregnancy, miscarriage, and abortion 
rates among various ages in the United States and Massachusetts, and prenatal clinical 
care plans to compare them to the Synthea care plan. The clinical care plans chosen to 
compare Synthea to were the University of Michigan Medicine: Prenatal Care 
Guidelines for Clinical Care Ambulatory and National Guideline Clearinghouse: Routine 
Prenatal Care.  
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Dr. Susan Haas gave suggestions for edits of this module as well, going through 
three rounds of review and feedback. After making edits to the module, the generated 
flow-chart image of the module were reviewed with Dr. Haas. She was able to provide 
insight into which practices are no longer standard, the timeline of procedures and 
appointments, follow-up care, and appropriate SNOMED-CT terminology. 
 
Objective III: Create, Validate, and Verify Population Disease 
Prevalence Report 
First, a prevalence CSV template was made, to be populated after the statistics 
have been calculated. Next, a database was populated with generated living patients, 
from the java version of Synthea. The first SQL queries were to find total counts for 
diabetes prevalence among different races and genders for adults (18 years and 
above), then this query was used this as a template to expand on to Hypertension, 
Coronary Heart Disease, and Asthma. All of these queries were written in SQL.  
The queries were executed in Java by creating a string builder that adds 
additional lines to an initial query depending on the disease, gender, age group, and 
race that was on a specific line in the template. The additional strings, containing 
queries for these descriptors, would be executed if an “*” was not found on that line 
(which indicates all) and would insert the description (i.e. “native”) into the query. This 
was an efficient way to query based on the contents of the report template.  
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The total count of these queries is divided by the total count of living patients 
within that demographic in order to get the Synthea prevalence rate of that specific 
disease among the defined demographic. A similar string building technique was used 
to run the queries for population. The Synthea prevalence rate was also converted to a 
percent, and compared against the actual prevalence rate percentages. Finally a 
difference between the two was calculated, if an actual prevalence rate was found for 
that specific line in the report. It proved to be difficult to find prevalence rates for each 
demographic for every disease, as some diseases were not researched in such detail. 
However, as more data is published, the values can be inserted in the report and 
compared against the values generated in Synthea.  
Another piece of this report includes prevalence rates of one disease given that a 
person has one or two defined pre-existing conditions. The same techniques were used 
to find the total count of people and the prevalence, however this required joining 
multiple attribute tables instead of querying on just one. After completing the template 
and ensuring the queries and calculations worked, ten reports each of which contained 
1,000 living patients were generated. The results of the ten reports were then 
compared, looking for any prevalence percentages that were drastically different among 
the reports.  
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Implementation & Results 
Synthetic Patient Health Record Interviews 
On average, the doctors found the synthetic health records to be fairly realistic, 
with an average realism rating of 2.9375 on a scale of 1-5, 5 being very realistic. 
Additionally the doctors found that the importance of the missing information was 
around 3.875, 5 being very important. The interviewed doctors found the records to be 
realistic in how much information was missing at times, as it is common for records to 
be lacking in information as patients move from office to office. Another aspect found to 
be realistic is the smaller dosing of medications for children than adult dosages.  
Some aspects of the records were unrealistic as well. For example, patients were 
very disciplined about getting their flu shot each year, which is ideal but not realistic. 
Additionally, most patients received flu shots in the spring or summer months, when the 
flu shot is typically administered in fall and winter.  
 
Figure 2: Off-season influenza immunization 
Another unrealistic aspect of the records was that patients would receive drugs at 
a time before they was created. For example, synthetic patient Blair872 Doyle966 
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received PAClitaxel and Cisplatin for non-small cell lung cancer from 1972-1973, when 
those drugs were not approved by the FDA until 1993.  
 
Figure 3: PACLitaxel and Cisplatin medications before FDA approval 
Another example of an inaccuracy was that all prescription medications for 
penicillin were “current” medications in the record, meaning that once a patient was 
prescribed penicillin they were prescribed it for life.  
 
Figure 4: Penicillin prescription with no end date 
Some prescriptions were also unnecessary including an antibiotic, amoxicillin, for 
viral sinusitis on synthetic patient record Manuel709 Schmitt79.  
 
Figure 5: Antibiotic for viral condition 
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Another anomaly is that the patient records did not specify if the patient had no 
known allergies, it was only specified if the patient had allergies. This was a point of 
concern from the doctors who believed that it should state that there are no known 
allergies in the record.  
Additionally, the age of some pregnant mothers was unrealistic. For example, 
synthetic patient Christeen210 Bahringer247 was pregnant at ages 51, 47, 45, and 43, 
of which two of these pregnancies resulted in childbirth. Which is possible in the current 
day, likely through in vitro fertilization (IVF), but likely not in 1976 or earlier as the first 
successful birth from IVF occurred in 1978. Although she could have been pregnant, 
this would likely not be a normal pregnancy but rather a high risk pregnancy. It is also 
unlikely that she was able to have this many children at this age. Additionally this patient 
also had a history of heart disease and diabetes making these pregnancies even more 
unlikely at her age. 
 
Figure 6: Unlikely normal pregnancy 
It is important to note that the data collected is from five patient records, with 
opinions from six medical professionals. More information on realism and missing or 
incorrect information in Synthea could be found by using additional profiles and 
interviewing additional medical professionals.  
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Pregnancy Module 
The first shortcoming found is that the first prenatal appointment within Synthea 
is at 10 weeks, when this should actually be when the second prenatal appointment is 
occurring. This was fixed this to have an initial appointment at 6 weeks, with a follow up 
appointment at 10 weeks. There was a large gap between prenatal appointments two 
and three of 11 weeks, which is almost an entire trimester, so it is unlikely a pregnant 
women would not have an appointment for that long. To address this and be in 
accordance with clinical care plans, follow up appointments at weeks 16, 22, 28, 32, 36, 
38, 39, 40, 41, and 42 were also implemented.  
Another shortcoming was the lack of information recorded at each prenatal 
appointment. The types of information missing included blood tests, urine tests, 
ultrasounds, vaccinations, screenings, and care plans. The appropriate information, 
procedures, and observations were added to the appropriate prenatal appointments, 
according to the University of Michigan Medicine, National Guideline Clearinghouse, 
and expert suggestions. Additionally, an attribute for RH negative blood women was 
added, as they require additional screenings and procedures throughout the pregnancy 
module.  
The next shortcoming was that Synthea does not have postpartum care plans 
within the pregnancy module. The module ended the moment the mother gave birth and 
contained no follow up appointments or care plans following the birth. Additionally, there 
were no follow up appointments or care plans assigned following an induced termination 
of pregnancy. However there were follow up appointments following miscarriages, but 
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no assigned care plans. Follow up appointments were implemented and the appropriate 
care plans and necessary procedures performed at each of them. An option for a 
medically-induced termination of pregnancy following an ectopic pregnancy was 
implemented, as previously only surgically-induced termination of pregnancy was in the 
module. Additionally, the timing of birth was edited to be weighted more towards weeks 
37, 38, and 39, as it was previously weighed a lot heavier to the later weeks, and 
categorized births before 40 weeks as premature. 
After speaking with Dr. Susan Haas regarding the pregnancy module and asking 
for her insight on the edits and additions, a non-low-risk pregnancy pathway was 
implemented that can be expanded in the future. This non-low risk pathway would 
provide additional specialized care for expecting mothers including those with 
preeclampsia, diabetes, heart disease etc. The health records for pregnant women in 
Synthea are now much more complete with information about laboratory tests, 
ultrasounds, education, and follow-up appointments for birth, induced abortion, and 
miscarriages. It is important to note that the pregnancy module in Synthea is an 
abstraction of the standard of care, and does not account for additional factors such as 
insurance coverage in the care that is given, thus all patients receive the same level of 
care.  
Disease Prevalence Report 
Compiling the data from the ten reports, I found that Synthea is creating disease 
prevalence percentages that were on average +5.675% total difference from the actual 
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prevalence percentages, for all living adults. Going into each disease individually, 
diabetes prevalence differed by +26.9%, hypertension differed by 1.1%, coronary heart 
disease differed by -1.0%, and asthma differed by -4.3%.  
Table 1: Synthea disease prevalence compared to actual disease prevalence 
 Actual Prevalence 
Percent 
Synthea 
Prevalence 
Percent 
Difference 
Diabetes 8.0 39.4 26.9 
Hypertension 29.1 30.2 1.1 
Coronary Heart 
Disease 
6.0 5.0 -1.0 
Asthma 9.6 5.3 -4.3 
 
Additionally, the prevalence levels for all living adults in each of the ten reports 
were extremely similar, differing on average by less than 1% from report to report. Error 
in this prevalence report could also come from the published data, as the prevalence 
rates may be different now than when the reports were last published. Additionally, 
comparing the total counts for unique conditions, and the prevalence percentages, 
Synthea was generating consistent counts in each report of 1,000 patients.   
Conclusion 
In conclusion, Synthea has proven to be a realistic yet synthetic patient 
generator. The majority of inaccuracies in the patient records are quick fixes, such as 
adding an end date to a penicillin prescription, putting a guard on certain drugs so that 
they cannot be administered before a certain year, and adding a restriction on the flu 
vaccine so that it is only available in the fall and winter months. The disease modules 
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themselves will continue to get more sophisticated and realistic as more people 
contribute to them. As these modules become more realistic, realistic disease 
prevalence levels among various demographics will follow. The suggested course of 
action is to begin by fixing the little things at the patient level like the drugs and 
vaccines. Next focusing on the modules, modeling them off published standards of care, 
consulting field experts on the changes being made, and putting in detailed care plans. 
Once the small details are fixed and the modules are more detailed, the prevalence 
data will follow.  
This MQP serves as a repeatable process for identifying areas of improvement of 
Synthea in the future. Interviewing medical doctors regarding the realism of patient 
records highlights the areas in Synthea that may need improvement. Comparing the 
modules to published care plans and consulting a field expert for multiple rounds of 
review is helpful in creating the most detailed and accurate abstractions of care 
possible. Finally, after editing the modules, and creating the disease prevalence report, 
it can be seen which diseases are occurring too often or not often enough. From there 
the disease modules can be altered again to produce more realistic values.  
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